GIP, GLP-1,
Last reviewed: July 7, 2026 Last updated: July 7, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
The random urine ACR corrects for urinary concentration and compares very well to the degree of albuminuria measured in a properly done 24-hour urine collection [28]
This led to further double-blinded, randomized, placebo-controlled trials examining the effects of semaglutide and tirzepatide in patients with obesity, but who did not have type 2 diabetes
Looking toward the future The wheels of progress on multi-agonists, oral small molecules, and tissue-targeted approaches are moving forward at breakneck speed